Signaturefd LLC reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 32.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 79,623 shares of the biopharmaceutical company's stock after selling 37,464 shares during the quarter. Signaturefd LLC's holdings in Pfizer were worth $2,112,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the fourth quarter worth about $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer during the third quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several research firms have recently weighed in on PFE. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.92.
View Our Latest Analysis on PFE
Insider Activity at Pfizer
In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.
Pfizer Price Performance
Shares of PFE stock traded down $0.12 during trading hours on Wednesday, reaching $26.19. The company's stock had a trading volume of 24,966,825 shares, compared to its average volume of 35,756,685. The firm's 50 day simple moving average is $26.21 and its 200-day simple moving average is $27.09. The company has a market capitalization of $148.44 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The company's revenue was up 24.7% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
